Interaction of Arrestin with Enolase1 in Photoreceptors

W. Clay Smith,1,2 Susan Bolch,1 Donald R. Dugger,1 Jian Li,1 Isi Esquenazi,1 Anatol Arendt,1 Del Benzenhafer,1 and J. Hugh McDowell1

PURPOSE. Arrestin is in disequilibrium in photoreceptors, translocating between inner and outer segments in response to light. The purpose of this project was to identify the cellular component with which arrestin associates in the dark-adapted retina.

METHODS. Retinas were cross-linked with 2.5 mM dithiobis(succinimidylpropionate) (DSP), and arrestin-containing complexes purified by anion-exchange chromatography. Tandem mass spectrometric analysis was used to identify the protein components in the complex. Enolase localization in photoreceptors was assessed by immunohistochemistry. Confirmation of interacting components was performed using immunoprecipitation and surface plasmon resonance (SPR). Enolase activity was also assessed in the presence of arrestin1.

RESULTS. In retinas treated with DSP, arrestin cross-linked in a 125-kDa complex. The principal components of this complex were arrestin1 and enolase1. Both arrestin1 and -4 were pulled down with enolase1 when enolase1 was immunoprecipitated. In the dark-adapted retina, enolase1 co-localized with arrestin1 in the inner segments and outer nuclear layer, but remained in the inner segments when arrestin1 translocated in response to light adaptation. SPR of purified arrestin1 and enolase1 demonstrated direct binding between arrestin1 and enolase1. Arrestin1 modulated the catalytic activity of enolase1, slowing it by as much as 24%.

CONCLUSIONS. The results show that in the dark-adapted retina, arrestin1 and -4 interact with enolase1. The SPR data show that the interaction between arrestin1 and enolase1 is direct, not requiring a third element to form the complex. Arrestin1 slowed the catalytic activity of enolase1, suggesting that light-driven translocation of arrestin1 may modulate the metabolic activity of photoreceptors. (Invest Ophthalmol Vis Sci. 2011;52:1832-1840) DOI:10.1167/iovs.10-5724

Rod and cone photoreceptors are highly specialized cells in the mammalian retina that capture photons and transduce light energy into a change in membrane potential that is ultimately relayed to the visual cortex. Photons are absorbed in these photoreceptors by opsins-based visual pigments to initiate the phototransduction cascade. The activity of the visual pigment is regulated by the arrestin family of proteins, 45-kDa proteins that sterically occlude access of transducin to the activated visual pigment until the vitamin A-derived chromophore is released and the rhodopsin is regenerated with 11-cis retinal (recently reviewed in Ref. 1).

Since arrestin functions to quench phototransduction, one would expect it to be primarily concentrated in photoreceptor outer segments where the visual pigment resides. Instead, the distribution of arrestin is quite dynamic, primarily localizing to the inner segments and perinuclear region of photoreceptors in the dark and then translocating to the outer segments during light adaptation.2–6 This light-dependent change in arrestin distribution has been noted in both rods4,7,8 and cones.5,6,9 The function of arrestin translocation is unclear, although it has been hypothesized to have a role in adapting the photoreceptor’s response to light, improving the temporal resolution of the photoresponse in background light.3 Since the translocation occurs on a time scale that is relatively slow, however, an alternative hypothesis for the function of arrestin translocation is that it provides protection for rods against light-induced damage resulting from continuous operation of the phototransduction cascade.10

The mechanism of arrestin translocation has been investigated by various laboratories and revealed to be complex. It was originally proposed that arrestin translocation could be accounted for by a two-partner, diffusion-mediated model in which arrestin binds to activated rhodopsin in the outer segments in the light and microtubule elements in the inner segments in the dark.11,12 The diffusion of arrestin through the connecting cilium is sufficiently fast to account for the translocation of arrestin in response to light.5,13 However, it is clear that arrestin translocation is more complex, with a signaling cascade regulating the initial translocation of arrestin15 and with more molecules of arrestin moving to the outer segments than the number of rhodopsin molecules bleached at threshold levels of light.3 This initial signaling of arrestin translocation appears to be accomplished by a phospholipase C cascade.15 In addition to this involvement of a signaling cascade, arrestin translocation also appears to be facilitated by cytoskeletal elements, with microtubules assisting in the distribution of arrestin to the apical end of the outer segments16,17 and microfilaments facilitating the movement of arrestin from the outer segments to the inner segments.17

Although the evidence supporting arrestin binding to microtubules in vitro is quite strong,18–20 the immunohistochemical data do not completely agree with tubulin/microtubules serving as the binding sink in the inner segments of dark-adapted rods. For example, binding of arrestin to microtubules in dark-adapted rod inner segments would be expected to generate a more linear or cross-hatched distribution of arrestin. This has not been observed in any of the studies of arrestin localization, whether studied by immunostaining2,21 or direct observation of fluorescently tagged arrestin2,13 or whether studied at the confocal2,21 or ultrastructural level.22 In all these studies, the distribution of arrestin is relatively uniform, occupying the available cytoplasmic volume of the inner segments.
Since arrestin appears to have a relatively uniform distribution in the cytoplasm of the rod inner segments, we initiated this study to determine whether the localization of arrestin to the inner segments in the dark-adapted state might be through a specific association with a protein or complex other than the microtubule cytoskeletal elements. Using cross-linking agents in dark-adapted retinas, we show that arrestin and enolase1 are cross-linked, suggesting that they interact. This interaction is confirmed in multiple manners, using immunoprecipitation, SPR, and an enolase activity assay. We demonstrate that this interaction is direct between the two molecules, not requiring any additional binding elements.

**METHODS**

**Animals**

The use of all animals and animal tissues was in accordance with the institutional guidelines of the University of Florida’s Institutional Animal Care and Use Committee and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

**Protein Cross-linking**

A portion of a dark-adapted bovine retina (Lawson, Inc., Lincoln, NE) or freshly isolated, whole *Xenopus* retina was placed in 100 mM sodium phosphate buffer (pH 7.0) with 7.5 mM sodium chloride. Dithiobis(succinimidylpropionate) (DSP) in 100% DMSO was added to a final concentration of 2.5 mM in 10% DMSO (an equivalent volume of DMSO was added to unlinked control sample). The solution was vortexed to dispense the retina and incubated at room temperature for 1 hour. The sample was thoroughly homogenized in a glass–glass homogenizer, and centrifuged (30,000 g, 30 minutes, 4°C) to produce a cleared supernatant for Western blot analysis. For experiments investigating arrestin4, the pellet from this centrifugation was retained, resuspended in Laemmli’s sample buffer, and also included for Western blot analysis.

In experiments for mass spectrometric identification of cross-linked proteins, the cross-linked supernatant was also purified over an immobilized papain digestion column (Biorad, Hercules, CA) and digested with trypsin. The resulting peptides were purified over a C18 HPLC column (LC Packings PepMap; Dionex, Sunnyvale, CA) and desalted for 5 minutes with a 10 mM/LiCl flow rate of 0.1% vol/vol acetic acid. The samples were loaded onto a C18 HPLC column (LC Packings PepMap; Dionex). The elution gradient of the HPLC column started at 3% solvent A and 97% solvent B and finished with 60% solvent A and 40% solvent B for 60 minutes for protein identification (solvent A: 0.1% vol/vol acetic acid, 3% vol/vol acetonitrile, and 96.9% vol/vol water; solvent B: 0.1% vol/vol acetic acid, 96.9% vol/vol acetonitrile, and 3% vol/vol water). LC-MS/MS analysis was performed on a hybrid quadrupole-TOF mass spectrometer (QSTAR; Applied Biosystems, Inc. [ABI], Framingham, MA). The focusing potential and ion spray voltage were set to 275 and 2600 V, respectively. The information-dependent acquisition (IDA) mode of operation was used in which a survey scan from m/z 400 to 1200 was acquired, followed by collision-induced dissociation of the three most intense ions. Survey and MS/MS spectra for each IDA cycle were accumulated for 1 and 3 seconds, respectively.

**Protein Search Algorithm**

Tandem mass spectra were extracted (Analyst version 1.1; ABI). All MS/MS spectra were analyzed using Mascot (ver. 2.0.01; Matrix Science, London, UK). Mascot was set up to search the NCBInr database assuming trypsin as the digestion enzyme (Mascot is available in the public domain at www.matrix.com). Mascot was searched with a fragment ion mass tolerance of 0.30 Da and a parent ion tolerance of 0.50 Da. Iodoacetamide derivative of Cys, deamination of Asn and Gln, and oxidation of Met were specified in Mascot as variable modifications. Protein identification software (Scaffold, ver. 01-06-03; Proteome Software Inc., Portland, OR) was used to validate MS/MS-based peptide and protein identification. Peptide identifications were accepted if they could be established at greater than 95.0% probability as specified by the Peptide Prophet algorithm.26 Protein identifications were accepted if they could be established at greater than 99.0% probability and contained at least two identified unique peptides. Protein probabilities were assigned by the Protein Prophet algorithm.27

**Antibody Preparation**

A 12-amino-acid peptide from bovine enolase1 N terminus (MSLKLVAREIF) was synthesized at 0.1 mmol scale, by solid phase, using Fmoc derivatives of amino acids, with automatic synthesizer (model 431A; ABI). Multiple copies of the peptides were synthesized on an inert lysine core with eight-branched MAPS resin (Ana Spec, San Jose, CA), after the DCC/HOBt protocol. The completed peptide was cleaved from resin using 95% trifluoroacetic acid with 2.5% trisopropylsilane and 2.5% water for 2 hours. The peptide was precipitated from solution using cold diethyl ether and lyophilized.

The octamer peptide or full-length His (6)-tagged bovine enolase1 purified from yeast (described below) was dissolved in phosphate-buffered saline and injected into BALB/c mice for the production of monoclonal antibodies. Hybridoma cultures were cloned and screened against purified full-length bovine enolase1, 2, and 3 that were heterologously expressed in bacteria to identify monoclonal antibodies that were specific to enolase1. To obtain the enolase isoforms, cDNAs for bovine enolase1, 2, and 3 were amplified from bovine retinal poly(A) RNA that had been reverse transcribed after priming with oligo(dT). PCR primers were used that incorporated EcoRI sites flanking the open reading frame. The 5′ primer also incorporated a His(6)-tag between the initiating methionine codon and second codon. Bovine enolases were cloned into the EcoRI site of pET-28a (Novagen, Madison, WI), and expressed in the BL21(DE3) strain of *Escherichia coli*. Cultures were grown overnight at 30°C with 30 μM isopropyl β-D-thiogalacto-pyranoside to induce expression of the enolases. Bacterial cultures were disrupted with a French press (20,000 psi) in 50 mM sodium phosphate buffer with 300 mM NaCl and 10 mM imidazole (pH 8.0), and the enolase purified to >95% homogeneity by affinity purification on a His column (Gravi-Trap; GE Life Sciences, Piscataway, NJ), eluting with the same buffer containing 500 mM imidazole. Eluted samples onto a capillary trap (LC Packings PepMap; Dionex, Sunnyvale, CA) and desalted for 5 minutes with a 10 μM/LiCl flow rate of 0.1% vol/vol acetic acid. The samples were loaded onto a C18 HPLC column (LC Packings PepMap; Dionex). The elution gradient of the HPLC column started at 3% solvent A and 97% solvent B and finished with 60% solvent A and 40% solvent B for 60 minutes for protein identification (solvent A: 0.1% vol/vol acetic acid, 3% vol/vol acetonitrile, and 96.9% vol/vol water; solvent B: 0.1% vol/vol acetic acid, 96.9% vol/vol acetonitrile, and 3% vol/vol water). LC-MS/MS analysis was performed on a hybrid quadrupole-TOF mass spectrometer (QSTAR; Applied Biosystems, Inc. [ABI], Framingham, MA). The focusing potential and ion spray voltage were set to 275 and 2600 V, respectively. The information-dependent acquisition (IDA) mode of operation was used in which a survey scan from m/z 400 to 1200 was acquired, followed by collision-induced dissociation of the three most intense ions. Survey and MS/MS spectra for each IDA cycle were accumulated for 1 and 3 seconds, respectively.

**Antibody Preparation**

A 12-amino-acid peptide from bovine enolase1 N terminus (MSLKLVAREIF) was synthesized at 0.1 mmol scale, by solid phase, using Fmoc derivatives of amino acids, with automatic synthesizer (model 431A; ABI). Multiple copies of the peptides were synthesized on an inert lysine core with eight-branched MAPS resin (Ana Spec, San Jose, CA), after the DCC/HOBt protocol. The completed peptide was cleaved from resin using 95% trifluoroacetic acid with 2.5% trisopropylsilane and 2.5% water for 2 hours. The peptide was precipitated from solution using cold diethyl ether and lyophilized.

The octamer peptide or full-length His (6)-tagged bovine enolase1 purified from yeast (described below) was dissolved in phosphate-buffered saline and injected into BALB/c mice for the production of monoclonal antibodies. Hybridoma cultures were cloned and screened against purified full-length bovine enolase1, 2, and 3 that were heterologously expressed in bacteria to identify monoclonal antibodies that were specific to enolase1. To obtain the enolase isoforms, cDNAs for bovine enolase1, 2, and 3 were amplified from bovine retinal poly(A) RNA that had been reverse transcribed after priming with oligo(dT). PCR primers were used that incorporated EcoRI sites flanking the open reading frame. The 5′ primer also incorporated a His(6)-tag between the initiating methionine codon and second codon. Bovine enolases were cloned into the EcoRI site of pET-28a (Novagen, Madison, WI), and expressed in the BL21(DE3) strain of *Escherichia coli*. Cultures were grown overnight at 30°C with 30 μM isopropyl β-D-thiogalactopyranoside to induce expression of the enolases. Bacterial cultures were disrupted with a French press (20,000 psi) in 50 mM sodium phosphate buffer with 300 mM NaCl and 10 mM imidazole (pH 8.0), and the enolase purified to >95% homogeneity by affinity purification on a His column (Gravi-Trap; GE Life Sciences, Piscataway, NJ), eluting with the same buffer containing 500 mM imidazole. Eluted samples
were dialyzed against phosphate-buffered saline. Hybridomas Enol1-8, Enol2-53, and Enol2-55 were tested against heterologously expressed bovine enolase1, -2, and -3 and shown to be specific for enolase1 (Supplementary Fig. S1, http://www.iovs.org/lookup/suppl/doi:10.1167/iovs.10-5724/s/DCSupplemental).

**Immunoprecipitation**

Samples of bovine retina treated as above with 2.5 mM DSP (or DMSO as a non–cross-link control) were immunoprecipitated using protein G-coated magnetic beads (Dynal; Invitrogen). The beads were loaded with purified anti-enolase1 monoclonal antibody (Enol1-8) or with anti-enolase2 monoclonal antibody (SC-21738; Santa Cruz Biotechnology); beads with no antibody or with anti-transducin α-subunit antibody (SC-389; Santa Cruz Biotechnology) were used as controls for non-specific binding. Retinal extracts were applied to the beads, incubated for 1 hour (25°C), and then captured magnetically. After washing the beads in phosphate buffer, bound protein was eluted with Laemmli sample buffer and subjected to Western blot analysis. All immunoprecipitation procedures were performed using dark-adapted bovine retinas in dim red illumination. Blots were probed with anti-enolase1 (Enol1-81), anti-arrestin1 (SCT-126), anti-arrestin1 (xCAR2-166), anti-transducin,10 or anti-tubulin (SC-5546; Santa Cruz Biotechnology) antibodies.

**Immunohistochemistry**

Wild-type *Xenopus laevis* tadpoles were either dark adapted overnight or exposed to laboratory lighting (800 lux) for 1 hour and then fixed in methanolic formaldehyde as previously described.2 Cryosections were probed with an anti-enolase1 monoclonal antibody (Enol2-53, IgG1) and a mouse anti-arrestin1 monoclonal antibody (XAR1–6, 2 μg/ml) and subjected to Western blot analysis. All immunoprecipitation procedures were performed using dark-adapted bovine retinas in dim red illumination. Blots were probed with anti-enolase1 (Enol1-81), anti-arrestin1 (SCT-126), anti-arrestin1 (xCAR2-166), anti-transducin,10 or anti-tubulin (SC-5546; Santa Cruz Biotechnology) antibodies.

**Protein Purification for SPR and Biochemical Assays**

To obtain enolase that was free of all extraneous sequence, except for an N-terminal His (6) tag, bovine enolase1 cDNA was excised from the above-described PET-28 expression vector with EcoRI, cloned into the EcoRI site of pPIC-ZA (Invitrogen), and stably recombined into the *Pichia* genome. Yeast cultures were disrupted with a French press (20,000 psi) in 50 mM sodium phosphate buffer with 300 mM NaCl and 10 mM imidazole (pH 8.0), and the enolase purified to >95% homogeneity by affinity purification on a His column (GraviTrap; GE Life Sciences), eluting with the same buffer containing 500 mM imidazole. Eluted samples were dialyzed against 15 mM Tris-HCl (pH 7.4) with 1 mM MgCl2, 1 mM CaCl2, and 0.1 mM DTT, and stored at –80°C.

Bovine arrestin1 was either purified from bovine retinal homogenates as described elsewhere,20 and subsequently modified,29 or was purified from *Pichia pastoris* where it was expressed with an N-terminal His (6) tag, as previously described.30,31 To control for potential effects from small amounts of contaminating proteins, we subjected an extract from nonrecombinant *Pichia* (strain GS115) to the identical purification procedure and used in the catalytic assay described below.

**Surface Plasmon Resonance**

All SPR data were collected on a protein-interaction analysis system (Biacore 3000 GE Healthcare). Arrestin1, purified from bovine retinas, was immobilized to a sensor chip (Biacore CM4; GE Healthcare) via amine coupling, by using the immobilization wizard according to the manufacturer's manuals. The carboxylated dextran matrix on the sensor chip surface was equilibrated with 50 mM NaPO4, 50 mM NaCl (pH 7.0) containing 0.01% P20 surfactant (GE Life Sciences). The carboxyl groups were then activated with a 50 mM N-hydroxysuccinimide (NHS) and 200 mM N-ethyl ([dimethylamino]propyl)carbodiimide. Arrestin1, diluted 1:20 with sodium acetate buffer (pH 5.5) to a concentration of 43 μM, was used for linking to the surface at 1000 refraction units (RU). The remaining activated carboxyl groups were blocked by reacting with 1 M triethylamine (pH 8.5).

The interaction between enolase1 and arrestin1 was monitored by SPR (BIAcore 3000; GE Healthcare). Enolase1 prepared as just described from *Pichia* was dialyzed against 50 mM NaPO4, 50 mM NaCl, 1 mM MgCl2 (pH 7.0) containing 0.05% Tween 20. The dialysis buffer was used as the running buffer in the experiments. For regeneration of the surface, 50 to 150 μL of regeneration solution (50 mM NaPO4, 1.05 M NaCl, 1 mM MgCl2 [pH 7.0]), containing 0.05% Tween 20) was injected at the end of each analysis cycle.

**Enolase Catalytic Activity**

The enzymatic activity of enolase1 was measured by monitoring the loss of absorbance at 340 nm, as NADH is oxidized when 2-phosphoglycerate is converted to lactic acid.52 Briefly, bovine enolase1 (purified from *Pichia*) was dialyzed into 15 mM Tris-HCl with 1 mM MgCl2, 1 mM CaCl2, and 0.1 mM DTT (pH 7.4). Enolase1 was added at a final concentration of ~77 nM to a reaction mix containing 2 mM 2-phosphoglycerate, 3 U/mL pyruvate kinase (Sigma-Aldrich), and 3.6 U/mL lactate dehydrogenase (Sigma-Aldrich) in 15 mM Tris-HCl with 25 mM MgSO4, 100 mM KCl, 0.2 mM NADH, 2 mM ADP, 0.02% (wt/vol) bovine serum albumen, and 0.01% P20 surfactant. In some experiments, bovine arrestin1 purified from heterologous expression in yeast was added in increasing amounts (0–32 μM). The reaction mix was prewarmed to 25°C and maintained at 25°C in a Peltier-controlled cuvette holder during the 10-minute reaction time. The rate of enolase activity was determined from a linear fit of the decline in absorbance at 340 nm for data collected at 1-minute intervals over 1 to 10 minutes. To control for effects contributed by contaminating components in the purified protein preparations, we used an extract prepared from nonrecombinant yeast (described above) in volumes equivalent to that used for arrestin1.

**Results**

**Cross-linking of Arrestin in Retina**

Studies have shown that arrestin1 is in disequilibrium in dark-adapted rod photoreceptors, primarily localizing to the rod inner segments.2–4 This distribution was unexpected, given arrestin’s high cytosolic solubility. In an effort to identify the cellular component(s) that might maintain this disequilibrium in the dark-adapted rod, we attempted to cross-link arrestin1 in situ using DSP to form a stable complex of arrestin1 with the proteins in near proximity. Figure 1A shows a Western blot stained with an anti-arrestin1 monoclonal antibody, comparing extracts of untreated bovine retina (lane 1) with an extract from a retina treated for 1 hour with DSP cross-linker (lane 2). In the untreated retina, a prominent doublet was present at ~48 and ~44 kDa, representing full-length arrestin and its shorter splice variant form.33 In the retina treated with DSP cross-linker, an additional doublet was detected at ~110 and 125 kDa. A similar complex at ~125 kDa was formed in retinas from adult *Xenopus* treated with the DSP cross-linker (see Fig. 3A).

To identify the components of this higher-molecular-mass band, we prepared soluble extracts separately from both bovine and *Xenopus* retinas that were cross-linked with 2.5 mM DSP in phosphate buffer, and the soluble components purified using DEAE anion-exchange chromatography. Fractions containing the higher-molecular-mass product (as determined by anti-arrestin1 Western blot analysis) were separated on 4% to 15% gradient SDS-PAGE, and although they contained a complex mixture of proteins, a distinct band was visible at ~125 kDa with Coomassie blue staining that corresponded to the band recognized by the anti-arrestin1 antibody on Western blot (Fig. 3A).
Figure 1. Arrestin-containing complexes in retina cross-linked with DSP.
(A) Western blot of retinal extracts prepared from dark-adapted bovine retina treated with 10% DMSO only (lanes 1, 3, 5) or with 2.5 mM DSP in 10% DMSO (lanes 2, 4, 6). Replicate blots were probed with anti-arrestin1 monoclonal antibody SCT-128 (lanes 1, 2), with anti-enolase1 antibody NB100 (lanes 3, 4), or with anti-enolase2 antibody SC-21758 (lanes 5, 6).

Arrowhead: an arrestin1-containing complex at 125 kDa. (B) Coomassie blue-stained gel (lane 1) and corresponding Western blot (lane 2) of extracts prepared from DSP-cross-linked bovine retinas that were fractionated by anion-exchange chromatography; Western blot strip (lane 1) was probed with anti-arrestin1 antibody. Western blot analysis of cross-linked bovine retinal samples (Fig. 1A, lanes 3, 4 for bovine; Fig. 3A, lanes 3, 4 for Xenopus) shows that the 125-kDa band (the expected size of monomeric enolase) and the 125-kDa band, which is also recognized by the anti-arrestin1 antibody. To determine whether this cross-linking is specific for the enolase1 isoform of enolase, we probed a replica blot with an antibody specific for enolase1 (Enol2-81), aldolase C, glutamate dehydrogenase, or lactate dehydrogenase.

Since cross-linking has the potential to artificially link proteins that are in very close proximity, but without any direct association, the interaction between enolase1 and arrestin1 was confirmed by immunoprecipitation with an anti-enolase1 antibody (Fig. 2). Bovine retinas that had been treated with 2.5 mM DSP cross-linker or left untreated were incubated with magnetic beads coated with protein G and Enol1-8 monoclonal antibody. Western blot analysis of the precipitated material showed that the enolase1 antibody captured both enolase1 (Fig. 2A) and arrestin1 (Fig. 2B). Importantly, arrestin1 was pulled down, even in retinal extracts that had not been stabilized by the DSP cross-linker. To determine whether tubulin was also immunoprecipitated with enolase1 and arrestin1, a replica blot was probed with anti-tubulin antibody (Fig. 2C). No reactivity was noted, even though the control (Fig. 2C, inset) showed that the anti-tubulin antibody recognizes a robust band in the whole retinal extract. The association between arrestin1 and enolase appears to be specific for the enolase1 isoform, since immunoprecipitation with an enolase2-specific antibody did not pull down any arrestin1 (Fig. 2D); the control blot developed with an enolase2 antibody demonstrates that the enolase2 antibody was effective at pulling down enolase2 (Fig. 2E). Additional control blots without any precipitating antibody (Figs. 2F, 2G) or with an irrelevant antibody (Figs. 2F, 2G) showed that the control (Fig. 2C, inset) showed that the anti-tubulin antibody recognizes a robust band in the whole retinal extract. The association between arrestin1 and enolase appears to be specific for the enolase1 isoform, since immunoprecipitation with an enolase2-specific antibody did not pull down any arrestin1 (Fig. 2D); the control blot developed with an enolase2 antibody demonstrates that the enolase2 antibody was effective at pulling down enolase2 (Fig. 2E). Additional control blots without any precipitating antibody (Figs. 2F, 2G) or with an irrelevant antibody (Figs. 2F, 2G) showed that the control (Fig. 2C, inset) showed that the anti-tubulin antibody recognizes a robust band.
anti-transducin-α antibody (Fig. 2H, 2I) did not pull down enolase1 or arrestin1.

To test whether the association of arrestin1 with enolase1 is dependent on the illumination conditions, we used adult Xenopus retinas, since the lighting conditions can be readily manipulated in the laboratory. Fresh retinas were isolated from adult Xenopus and then cross-linked with 2.5 mM DSP after the eyes had been either dark adapted for 3 hours or light adapted for 45 minutes (Fig. 3B). The 125-kDa complex was present only in extracts prepared from the dark-adapted eye.

**Figure 2.** Arrestin co-immunoprecipitates with enolase1. Bovine retinal extracts were either treated with DSP cross-linker (+) or 10% DMSO (−) and then immunoprecipitated with protein-G magnetic beads complexed with anti-enolase1 antibody (A–C), anti-enolase2 antibody (D, E), no antibody (F, G), or anti-transducin-α antibody (H, I). Captured proteins were eluted with SDS sample buffer and probed on Western blot analysis with anti-enolase1 (Enol2-81; A, F), anti-arrestin1 (SCT-128; B, D, G, I), anti-tubulin (SC-5546; C), anti-enolase2 (SC-21758; E), or a mixture of anti-enolase1 (Enol2-81) and anti-transducin α (SC-389; H). (C, inset) A Western blot of whole retina extract probed with the same anti-tubulin antibody, to demonstrate that the antibody recognizes tubulin in the bovine retina.

**Figure 3.** Cross-linking and immunohistochemical localization of enolase1 in Xenopus retina. (A) Retinas from Xenopus adults were treated with 2.5 mM DSP (lanes 2, 4) or with 10% DMSO (lanes 1, 3). Replica blots were probed with anti-arrestin1 (XAR1–6) or with anti-enolase1 (Enol2-53). (B) Western blot of retinal extracts prepared from adult Xenopus retinas that were dark adapted 3 hours (lane 1) or light adapted 45 minutes (lane 2) before 2.5 mM DSP was added. The blot was probed with anti-arrestin1 antibody SCT-128. (C–H) Immunolocalization of enolase1 and arrestin1 in (C–E) dark- or (F–H) light-adapted Xenopus tadpole eyes. Cryosections were stained for enolase1 (green) using anti-enolase1 antibody (Enol2-53) or arrestin1 (red) using anti-arrestin1 antibody (XAR1-6). Nuclear DNA was stained with DAPI (blue). RPE, retinal pigmented epithelium; OS, outer segments; IS, inner segments; ONL, outer nuclear layer; OPL, outer plexiform layer. Scale bar, 10 μm.

**Enolase Immunolocalization in Retina**

To determine whether enolase1 co-localized with arrestin in the photoreceptors, cryosections of Xenopus tadpole eyes were immunoprobed with an anti-enolase1 and anti-arrestin1 antibodies. In the dark-adapted Xenopus retina (Figs. 3C–E), enolase1 immunoreactivity was most abundant over the inner segments, the region surrounding the nuclei, the nuclei of rod and cone photoreceptors, and the outer plexiform layer (Fig. 3F). This distribution of enolase1 significantly overlapped that of arrestin1 in the dark-adapted retina (Fig. 3D). In the light-
Effects of Arrestin on Enolase Enzymatic Activity

Enolase is a glycolytic enzyme, functioning as a dehydrogenase converting 2-phosphoglycerate to phosphoenolpyruvate. In light of the direct interaction between enolase1 and arrestin1 identified by SPR, we next investigated whether arrestin1 modulates the catalytic activity of enolase1. In this assay, 77 nM enolase1 was mixed with 2-phosphoglycerate in the presence or absence of arrestin. Consumption of NADH was measured as an assay for the activity of enolase1. Figure 5 shows that under the conditions of our assay, the purified enolase1 catalyzes the hydrolysis of 2-phosphoglycerate at a rate of 2.55 mmol · min⁻¹ · g⁻¹ of enolase1. This catalytic activity is significantly slowed, however, by the addition of excess arrestin, approaching an asymptotic level of 1.92 mmol · min⁻¹ · g⁻¹. This difference represents a 24.7% reduction of the enolase1 activity in the presence of a 400-fold excess of arrestin1. The concentrations of arrestin1 and enolase1 used in this assay are significantly below the physiological concentrations, with arrestin1 being present in rod photoreceptors at ~1 mM, and enolase1 being approximately fivefold less at ~200 μM. Since we are using heterologously expressed and purified bovine arrestin1 from Pichia, the possibility exists that a minor contaminating component could be the source of this inhibitory effect. To address this possibility, we repeated the assay using an extract of nonrecombinant Pichia prepared in the same manner as we purify the bovine arrestin1. No effect on enolase catalytic activity was noted (data not shown).

Association of Enolase1 with Arrestin4

Since enolase1 is present in both rod and cone photoreceptors, we investigated whether enolase1 might also interact with arrestin4. Bovine retinal extracts were treated as previously described, by incubated with 2.5 mM DSP or carrier and then separating the extract into aqueous soluble and insoluble components by centrifugation. Replica Western blot analysis of these samples (Figs. 6A–C) show that the monomeric form of arrestin1 and the 125-kDa complex containing arrestin1 remain in the soluble fractions (Fig. 6A, lanes 1, 2). In contrast, arrestin4 moves to the aqueous-insoluble fraction in the presence of DSP, as does a second band containing arrestin4 at 125 kDa (Fig. 6B). When this blot is probed for the presence of enolase1, enolase1 immunoreactivity is noted not only in the aqueous-soluble sample at both 50 and 125 kDa, but also in the aqueous-insoluble fraction of the DSP sample at both 50 and 125 kDa (Fig. 6C). This observation prompted us to reinvestigate our immunoprecipitation experiment using a total retinal homogenate rather than simply the aqueous soluble fraction. Using an anti-enolase1 antibody as the precipitating antibody, arrestin4 could be detected in the immunoprecipitate in samples, both with and without DSP cross-linker (Fig. 6D, lanes 13.
enolase1.

species relevance for the interaction between arrestin1 and enolase1. No evidence is provided, however, that would distinguish enolase2 from enolase1. The interaction between arrestin1 and enolase is apparently species specific for the enolase1 isoform based on the following evidence. First, enolase2 was not identified in our tandem mass spectrometry analysis of the cross-linked complex, nor was it detected in two species (cow and Xenopus), indicating a broad species relevance for the interaction between arrestin1 and enolase1.

The interaction of arrestin1 with enolase is apparently specific for the enolase1 isoform based on the following evidence. First, enolase2 was not identified in our tandem mass spectrometry analysis of the cross-linked complex, nor was it detected in the complex by Western blot analysis. In addition, immunoprecipitation of enolase2 did not pull down any arrestin1, our data also suggest that a similar interaction occurs with arrestin4. The supporting evidence is twofold (Fig. 6): First, enolase1 cross-linked to arrestin4 in the presence of DSP. Unlike the complex formed with arrestin1, the enolase1/arrestin4 complex was aqueous insoluble. This shift in solubility likely explains why arrestin4 was not identified as one of the potential binding partners by mass spectrometric analysis since only the soluble fraction was retained for enrichment by anion-exchange chromatography. The second supporting line of evidence is that arrestin4 was immunoprecipitated by enolase1. Although the evidence for the interaction of arrestin4 with enolase1 is not as complete as we have developed for arrestin1, the association does appear to be credible.

Immunolocalization of enolase1 in the outer retina indicates that enolase1 shares a significant overlap with arrestin1 in dark-adapted rod photoreceptors, primarily in the inner segments and outer nuclear layer. In these regions, the distribution of enolase1 is diffuse, similar to that of arrestin. The localization of enolase1 is consistent with that of other glycolytic enzymes (e.g., glyceraldehyde-3-phosphate dehydrogenase and lactate dehydrogenase) which are principally localized to the inner segments and outer nuclear layer, but with a smaller portion localized in the outer segments. In addition to the co-localization with arrestin1, enolase1 is also significantly localized to the nuclei of rods and cones. This nuclear localization for enolase1 has been documented in other tissues where enolase1 serves as a transcription repressor.

It is curious that in both our cross-linking and immunoprecipitation studies, we did not find an association of arrestin1 with tubulin, as has been documented. Several possible explanations can be envisioned. For the cross-linking studies, it is simply possible that arrestin is not oriented in such a way with the microtubules to permit cross-linking by the DSP cross-linker. For the immunoprecipitation, a possible explanation is that since we are capturing arrestin1 that is associated with enolase1, tubulin may be sterically occluded from binding to arrestin, or we may be capturing a different population of arrestin molecules than those associated with microtubules. Alternatively, the affinity of arrestin to tubulin may be sufficiently low that tubulin would not remain associated with arrestin during the washes of the magnetic beads.

The blot was probed with arrestin4-specific monoclonal xCAR2-166.

14). A control immunoprecipitation with no antibody did not contain any arrestin4 immunoreactivity (Fig. 6D, lanes 15, 16).

**DISCUSSION**

This study reveals a previously unrecognized interaction between the visual arrestins and enolase1. Although this discovery was initially made using in situ cross-linking via DSP which can artificially stabilize proteins within 1.5 Å distance, the validity of the interaction was established using three additional approaches: (1) immunoprecipitation of arrestin via anti-arrestin1 antibodies, (2) measurement of enolase1 binding to arrestin1 via SPR, and (3) measurement of enolase1 catalytic activity in the presence of arrestin1. It is significant that immunoprecipitation of enolase1 pulled down arrestin1 even in the absence of DSP cross-linker, indicating that the association between arrestin1 and enolase1 is not artificially generated by the cross-linker. Importantly, our studies using SPR with purified enolase1 and arrestin1 provide a clear demonstration that these two proteins directly interact without requiring any additional scaffolding elements. These results, in their totality, provide convincing evidence that enolase1 interacts with arrestin1. It is significant that these observations were also replicated in two species (cow and Xenopus), indicating a broad species relevance for the interaction between arrestin1 and enolase1.

Our discovery of this direct interaction between enolase1 and arrestin1 is a new finding. The only previous link between these two proteins is a study showing that arrestin1 co-purified with several glycolytic enzymes, including enolase1 and -2, when using hydroxyapatite agarose chromatography. No evidence was provided, however, that would distinguish whether this co-purification was coincidental or whether these proteins were co-purifying as a complex.
While the manuscript for this article was under review, a report was published identifying a new interaction between arrestin1 and N-ethylmaleimide-sensitive factor (NSF). NSF was not identified as a binding partner for arrestin1 in our study for the following possible reasons: First, since NSF is primarily localized to the synaptic regions of the photoreceptors and enolase1 is found throughout the photoreceptor inner segments, it is possible that our immunoprecipitation of enolase1 was pulling down a different subcellular fraction of arrestin1 than that bound to NSF. Alternatively, binding of enolase1 to arrestin1 may block binding by NSF, thus preventing the concomitant immunoprecipitation of both arrestin1 and NSF with anti-enolase1 antibodies. With regard to why NSF was not identified in our mass spectroscopic analyses, in our study, we purified only the population of arrestin1 that was cross-linked into a larger complex. The absence of NSF in the complex suggests that when NSF is bound to arrestin1, it is not oriented in such a way that the DSP cross-linking agent can form an amide bond.

Modulation of Glycolysis by Arrestin

Enolases are a family of 48-kDa proteins that catalyze the dehydration of 2-phospho-D-glycerate to phosphoenolpyruvate in glycolysis. There are three isozymes—enolase1 (α-enolase), enolase2 (γ-enolase), and enolase3 (β-enolase)—that function as obligate homo- or heterodimers. Typically, enolase1 is broadly expressed in a variety of tissues, enolase2 is specific to neurons and neuroendocrine tissue, and enolase3 is found nearly exclusively in muscle. In contrast to arrestin1, enolase1 does not show any changes in distribution in response to light adaptation, indicating that lighting conditions could therefore modulate the interaction between these two proteins. This conjecture is supported by our cross-linking studies which show a dramatic reduction in cross-linking between arrestin1 and enolase1 in samples that have been light adapted (Fig. 3B). Our studies indicate that interaction between enolase1 modulates the activity of enolase1, reducing the catalytic rate by as much as 25%. Since the energetic demands of photoreceptors are enormous, estimated to be on the order of $10^9$ ATP · cell$^{-1}$ · s$^{-1}$, this modulation of enolase catalysis has potentially important implications. In the dark, nearly all of the ATP is consumed in pumping ions to maintain the ionic gradients of the photoreceptors. Because of the hyperpolarizing response of rods, exposure to bright light actually decreases ATP consumption by approximately 75%, despite the increased demand for ATP by the phototransduction components. In the dark-adapted state, arrestin1 primarily concentrates in the inner segments where enolase1 is most abundant and would thus have an inhibitory effect on the glycolytic rate. In response to light, most of the arrestin1 translocates to the outer segments, which would reduce the interaction with enolase1 in the inner segments and thus potentially increase the glycolytic rate when metabolic demand in terms of ATP is declining.

In light of this apparent contradiction, the interaction between arrestin and enolase1 may have more to do with the other arm of glycolysis—NADH production—than with supplying high energy ATP. NADH/NADPH is essential for the reduction of all-trans retinal produced by photosomerization of 11-cis retinal in rhodopsin and subsequent suppression of quantum noise. The upregulation of glycolysis by the translocation of arrestin1 away from enolase1 could provide additional NADH to facilitate this reduction of all-trans retinal. Another possibility for the interaction may be that arrestin1 serves as a scaffold in the dark-adapted state, building a complex of interactions that may relate to some as yet unidentified secondary function for enolase1 or other component of the complex. Arrestin’s function as a scaffolding agent has been well recognized for the β-arrestins (arrestin2 and -3) (reviewed in Ref. 45) and more recently for arrestin1.20

The Role of Enolase1 in Arrestin Translocation

These studies have identified an interaction of arrestin1 with enolase1, a protein that is principally (~90%) localized to the inner segment region. Could enolase1 be the binding partner that attracts arrestin1 and -4 to the inner segments during dark adaptation? At this point, the evidence is not conclusive, identifying only a binding interaction between two proteins that are in the right location in dark-adapted photoreceptors. Perhaps importantly, the cytosolic distribution of enolase1 matches that of arrestin much better than that of microtubules. Only additional studies will reveal whether enolase1 or tubulin (or both) serves as the binding sink that maintains arrestin in the inner segments in dark-adapted photoreceptors.

In summary, our studies provide the first evidence for direct interaction between enolase1 and arrestin1 and -4. The colocalization of arrestin1 and enolase1 in the inner segments of dark-adapted rod photoreceptors, coupled with the demonstrated modulation of enolase1 enzymatic activity by arrestin1, suggests an important role for this interaction in the retina.

Acknowledgments

The authors thank Eric Roush (GE Healthcare) for assistance with developing the SPR assay.

References

13. Peet JA, Bragin A, Calvert PD, et al. Quantification of the cytoplasmic spaces of living cells with EGF reveals arrestin-EGFP to be in...


